GlassScriptPhysician profile
Zuhaib Ibrahim
NPI 1780840173
$3,130.63
in general payments reported to CMS, 2019-2025
13 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $221 · 2021: $578 · 2022: $254 · 2023: $457 · 2024: $707 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.21 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $699.22 | 2019-2022 | |
| Abbvie INC. | $460.29 | 2023-2025 | |
| Mentor Worldwide LLC | $379.00 | 2021-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander, Mentor Cpx 2 Breast Tissue Expander |
| W. L. Gore & Associates, INC. | $302.83 | 2019 | |
| Axogen | $288.01 | 2019-2023 | Avance Nerve Graft |
| Musculoskeletal Transplant Foundation INC. | $257.33 | 2019-2025 | |
| Allergan, INC. | $155.72 | 2021-2022 | |
| Davol INC. | $128.23 | 2019 | |
| Tela Bio, INC. | $115.39 | 2021-2024 | Ovitex 2s |
| Checkpoint Surgical, INC | $101.03 | 2024 | Checkpoint Stimulators |
| Intuitive Surgical, INC. | $100.33 | 2023 | |
| Stryker Corporation | $100.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zuhaib Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.